The Keratoconjunctivitis drugs in development market research report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Keratoconjunctivitis. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Keratoconjunctivitis - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Keratoconjunctivitis and features dormant and discontinued products.

GlobalData tracks 187 drugs in development for Keratoconjunctivitis by 157 companies/universities/institutes. The top development phase for Keratoconjunctivitis is preclinical with 76 drugs in that stage. The Keratoconjunctivitis pipeline has 184 drugs in development by companies and three by universities/ institutes. Some of the companies in the Keratoconjunctivitis pipeline products market are: Azura Ophthalmics, Chongqing Kerun Biopharm R & D and Huons.

The key targets in the Keratoconjunctivitis pipeline products market include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16), Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1), and Integrin Alpha L (CD11 Antigen Like Family Member A or Leukocyte Adhesion Glycoprotein LFA 1 Alpha Chain or CD11a or ITGAL).

The key mechanisms of action in the Keratoconjunctivitis pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with 16 drugs in Pre-Registration. The Keratoconjunctivitis pipeline products include 17 routes of administration with the top ROA being Ophthalmic and 16 key molecule types in the Keratoconjunctivitis pipeline products market including Small Molecule, and Synthetic Peptide.

Keratoconjunctivitis overview

Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities.

For a complete picture of Keratoconjunctivitis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.